oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Von Beckerath, Mathias
Alternative names
Publications (10 of 11) Show all publications
Kristiansson, S., Reizenstein, J., Von Beckerath, M. & Landström, F. (2019). Long-term follow-up in patients treated with electrochemotherapy for non-melanoma skin cancer in the head and neck area. Acta Oto-Laryngologica, 139(2), 195-200
Open this publication in new window or tab >>Long-term follow-up in patients treated with electrochemotherapy for non-melanoma skin cancer in the head and neck area
2019 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 139, no 2, p. 195-200Article in journal (Refereed) Published
Abstract [en]

Background: Electrochemotherapy (ECT) is a cancer treatment modality where the intracellular accumulation of chemotherapeutic agents is enhanced by an applied electrical field.

Aims/Objectives: To evaluate the long-term efficacy, safety and functional outcome after ECT treatment in high-risk non-melanoma skin cancer (NMSC) with curative intent.

Materials and methods: Seven patients with SCC or BCC in the head and neck area were treated with ECT with intratumoral bleomycin administration.

Results: Five patients were cured by ECT as a mono-modality treatment after a median 10-year follow-up period. Two patients had recurrences and/or persisting tumors after treatment that required salvage surgery and radiotherapy. In two patients, the eye was spared with no visual impairment. In another patient, full facial nerve function was spared.

Conclusions: ECT can be a curative as well as an organ and function-sparing mono modality treatment in high-risk NMSC.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2019
Keywords
Electrochemotherapy, non-melanoma skin cancer, squamous cell carcinoma, basal cell carcinoma
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:oru:diva-73500 (URN)10.1080/00016489.2018.1543950 (DOI)000461648000014 ()30734631 (PubMedID)2-s2.0-85061282989 (Scopus ID)
Note

Funding Agency:

Örebro County Council

Available from: 2019-04-04 Created: 2019-04-04 Last updated: 2019-04-04Bibliographically approved
Mäkitie, A. A., Keski-Säntti, H., Markkanen-Leppänen, M., Bäck, L., Koivunen, P., Ekberg, T., . . . von Buchwald, C. (2018). Transoral Robotic Surgery in the Nordic Countries: Current Status and Perspectives. Frontiers in Oncology, 8, Article ID 289.
Open this publication in new window or tab >>Transoral Robotic Surgery in the Nordic Countries: Current Status and Perspectives
Show others...
2018 (English)In: Frontiers in Oncology, ISSN 2234-943X, E-ISSN 2234-943X, Vol. 8, article id 289Article in journal (Refereed) Published
Abstract [en]

Background: The five Nordic countries with a population of 27 M people form a rather homogenous region in terms of health care. The management of head and neck cancer is centralized to the 21 university hospitals in these countries. Our aim was to gain an overview of the volume and role of transoral robotic surgery (TORS) and to evaluate the need to centralize it in this area as the field is rapidly developing.

Materials and Methods: A structured questionnaire was sent to all 10 Departments of Otorhinolaryngology-Head and Neck Surgery in the Nordic countries having an active programme for TORS in December 2017.

Results: The total cumulative number of performed robotic surgeries at these 10 Nordic centers was 528 and varied between 5 and 240 per center. The median annual number of robotic surgeries was 38 (range, 5-60). The observed number of annually operated cases remained fairly low (<25) at most of the centers.

Conclusions: The present results showing a limited volume of performed surgeries call for considerations to further centralize TORS in the Nordic countries.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2018
Keywords
head and neck, surgery, management, centralization, cancer
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-68475 (URN)10.3389/fonc.2018.00289 (DOI)000439996700002 ()
Note

Funding Agencies:

Helsinki University Hospital Research Fund  TYH2017232 

Karolinska University Hospital Research Fund  ALF 20160596 

Finska Läkaresällskapet 

Available from: 2018-08-15 Created: 2018-08-15 Last updated: 2018-08-15Bibliographically approved
Landström, F., Reizenstein, J., Nilsson, C., von Beckerath, M., Löfgren, L., Adamsson, G.-B. & Möller, C. (2015). Electrochemotherapy - possible benefits and limitations to its use in the head and neck region. Acta Oto-Laryngologica, 135(1), 90-95
Open this publication in new window or tab >>Electrochemotherapy - possible benefits and limitations to its use in the head and neck region
Show others...
2015 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 135, no 1, p. 90-95Article in journal (Refereed) Published
Abstract [en]

Conclusion: Electrochemotherapy (ECT) is an efficacious treatment. It should, however, be used with some caution in the treatment of head and neck cancer.

Objectives: To assess local tumor control, safety, survival, and functional outcome after treatment of cancer in the head and neck region with ECT.

Methods: Four patients with primary T2 cancer of the oral cavity or oropharynx and one patient with a metastasis of renal cancer in the masseter muscle were treated with ECT with intratumorally administered bleomycin. Control biopsies were carried out 2 months after treatment. Postoperative radiotherapy was performed based on tumor T-stage and the depth of tumor infiltration. Serious adverse events and treatment malfunctions were recorded. The follow-up time was 24 months for the surviving patients and 20 months overall. The PSS-HN scale was used to assess the functional outcome.

Results: No local recurrence was recorded in any patient during the follow-up. However, only one patient was treated with ECT alone. There were four serious adverse events: one nearly lethal bleeding, two cases of osteoradionecrosis, and a fistula. One patient died from distant metastasis. The other patients were tumor-free both locally and overall at 24 months. The median functional outcome in all parameters was worse 1 year after treatment.

Place, publisher, year, edition, pages
Informa Healthcare, 2015
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:oru:diva-39848 (URN)10.3109/00016489.2014.947655 (DOI)000346275600013 ()25496181 (PubMedID)2-s2.0-84918592776 (Scopus ID)
Note

Funding agency: Genetronics Inc., San Diego, CA, USA

Available from: 2014-12-16 Created: 2014-12-16 Last updated: 2018-06-26Bibliographically approved
Landström, F., Ivarsson, M., von Sydow, A. K., Magnuson, A., von Beckerath, M. & Möller, C. (2015). Electrochemotherapy: Evidence for Cell-type Selectivity In Vitro. Anticancer Research, 35(11), 5813-5820
Open this publication in new window or tab >>Electrochemotherapy: Evidence for Cell-type Selectivity In Vitro
Show others...
2015 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 35, no 11, p. 5813-5820Article in journal (Refereed) Published
Abstract [en]

Aim: Electrochemotherapy (ECT) is a new cancer treatment modality that uses electroporation to potentiate chemotherapeutic agents, especially bleomycin. ECT causes both a direct toxic effect and an anti-vascular effect. The aim of the present study was to investigate a possible selective effect of ECT on the survival of fibroblasts, endothelial cells (HUVEC) and two squamous cell carcinoma cell lines (CAL-27 and SCC-4).

Materials and Methods: Cells were electroporated using two bleomycin concentrations. The survival rate was assessed 1, 2, 3 and 4 days after treatment, by two different assays.

Results: The survival rate of the fibroblasts was statistically significantly higher than the other cell lines at day 4. The HUVEC survival rate was statistically significantly lower than the other cell types at day 1 after electroporation-alone.

Conclusion: A selective survival effect after ECT was observed in vitro, supporting the anti-vascular effect seen in vivo.

Place, publisher, year, edition, pages
International Institute of Anticancer Research, 2015
Keywords
Electrochemotherapy, bleomycin, head and neck cancer, squamous cell carcinoma, fibroblasts, endothelial cells, selectivity
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-46832 (URN)000363794900010 ()26504002 (PubMedID)2-s2.0-84946055559 (Scopus ID)
Note

Funding Agency:

Örebro County Council

Available from: 2015-11-27 Created: 2015-11-27 Last updated: 2018-07-02Bibliographically approved
Landström, F., Reizenstein, J., Adamsson, G.-B., von Beckerath, M. & Möller, C. (2015). Long-term follow-up in patients treated with curative electrochemotherapy for cancer in the oral cavity and oropharynx. Acta Oto-Laryngologica, 135(10), 1070-1078
Open this publication in new window or tab >>Long-term follow-up in patients treated with curative electrochemotherapy for cancer in the oral cavity and oropharynx
Show others...
2015 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 135, no 10, p. 1070-1078Article in journal (Refereed) Published
Abstract [en]

Conclusion: ECT can be a safe curative mono modality treatment, especially in tongue cancer. The future role for ECT in head and neck cancer needs to be further investigated.

Introduction: Electrochemotherapy (ECT) is a cancer treatment modality that uses electroporation to increase the intracellular accumulation of hydrophilic chemotherapeutic drugs, especially bleomycin.

Objectives: To report the 5-year local tumor control, safety of treatment and survival after ECT, and the 1-year quality-of-life (QoL) data.

Materials and methods: Nineteen patients with primary head and neck cancer were included and treated with ECT with curative intent. All except one patient had squamous cell carcinoma (SCC). Radiotherapy (RT) was performed in all patients with SCC and tumor infiltration ‡5 mm. The EORTC H&N 35 questionnaire was used at baseline and 12 months after treatment. The Wilcoxon signed rank test and McNemar’s test were used for paired data and Mann Whitney U-test and Fishers exact test were used for independent data (sub-group comparison).

Results: There were no local recurrences in the follow-up period. Thirteen patients were treated with adjuvant RT. The six patients that were treated with ECT alone were tumor-free and alive 5 years after treatment. There was one serious adverse event reported; aspiration after treatment of a tongue base tumor. The tumor-specific 5-year survival was 75%. The QoL outcome 1 year after ECT showed a significant increase in problems with senses (taste, smell), speech, mouth opening and xerostomia. The QoL outcome also showed worse outcome in the smoking patients regarding speech, in the patients receiving adjuvant RT regarding mouth dryness and swallowing and in the patients with non-tongue oral cavity cancer regarding need for painkillers.

Keywords
Electrochemotherapy, bleomycin, head and neck cancer, squamous cell carcinoma, quality-of-life, local control, survival
National Category
Cancer and Oncology Otorhinolaryngology
Research subject
Oncology; Oto-Rhino-Laryngology
Identifiers
urn:nbn:se:oru:diva-45506 (URN)10.3109/00016489.2015.1049663 (DOI)000361294200016 ()26061895 (PubMedID)2-s2.0-84938901488 (Scopus ID)
Note

Funding Agencies:

Örebro County Council

Regional Board for Ethical Evaluation in Uppsala

Available from: 2015-08-10 Created: 2015-08-10 Last updated: 2018-07-01Bibliographically approved
von Beckerath, M. P., Reizenstein, J. A., Berner, A. L., Nordqvist, K. W. O., Landström, F. J., Löfgren, A. L. & Möller, C. (2014). Outcome of primary treatment of early laryngeal malignancies using photodynamic therapy. Acta Oto-Laryngologica, 134(8), 852-858
Open this publication in new window or tab >>Outcome of primary treatment of early laryngeal malignancies using photodynamic therapy
Show others...
2014 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 134, no 8, p. 852-858Article in journal (Refereed) Published
Abstract [en]

Conclusion: Photodynamic therapy (PDT) is a viable and safe option for early laryngeal cancer that would be less suitably treated with radiation or trans-oral laser surgery (TLS). The cure rates with PDT appear to be comparable to those of conventional therapy, and the voice outcomes are also comparable. In the case of many sarcomas, PDT appears to be an organ- and function-sparing therapy, although it is more costly than other treatments.

Objectives: The aim of this study was to show the results of PDT when it is used as a primary treatment of early laryngeal cancer. Methods: We studied the results of PDT when used as a primary treatment. We looked at survival, effect on tumor, side effects, voice, and costs.

Results: The follow-up period was a median of 59 months. Nine of 10 patients were cured of their laryngeal cancer. PDT alone cured seven patients. All four of the sarcomas were cured using temoporfin. Two of three tumors that involved the anterior commissure were cured using only interstitial illumination with PDT. No serious side effects were noted. The patient's voices were improved after treatment in 5 of 10 cases, and none had a worsened voice.

Keywords
Cancer, larynx, PDT, sarcoma, squamous cell carcinoma, porfimer sodium, temoporfin, voice
National Category
Otorhinolaryngology
Research subject
Oto-Rhino-Laryngology
Identifiers
urn:nbn:se:oru:diva-36374 (URN)10.3109/00016489.2014.906748 (DOI)000340137200013 ()24856450 (PubMedID)2-s2.0-84904327200 (Scopus ID)
Available from: 2014-09-03 Created: 2014-09-03 Last updated: 2018-06-09Bibliographically approved
von Beckerath, M. (2014). Photodynamic therapy in the head and neck. (Doctoral dissertation). Örebro: Örebro university
Open this publication in new window or tab >>Photodynamic therapy in the head and neck
2014 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Fotokemisk behandling av tumörer inom huvud- och halsområdet
Abstract [en]

Photodynamic therapy, PDT, is a method to diagnose and treat cancer. In PDT a sensitizer is administered to the patient and this sensitizer is accumulated in tumors. If the sensitizer-containing tumor is subjected to a laser of a specific wavelength the tumor is fluorescing allowing diagnostics. If other wavelengths are used a process involving reactive oxygen species and singlet oxygen is started and the tumor cells are killed. This process thus requires oxygen as well.

This thesis investigates how UV-induced damage of the skin and different physiological factors of the skin influences the uptake of 5- aminolevulinic acid, ALA, and its conversion to the active sensitizer protoporphyrin IX, PpIX. It shows that UV-induced damage affects both the uptake and production of PpIX. UV-induced damage lowers the PpIX produced after ALA application both if the damage is acute and in chronically UV-affected skin.

The PpIX production differs inter and intra individually. When looking how different physiological factors affect the PpIX production after topically applied ALA the thesis shows that an increase of temperature increases the production. No correlation between the formation of PpIX and the density of hair follicles was found and a weak correlation was seen comparing the epidermal and total dermal thickness and PpIX production

The thesis also shows how PDT is used in treating laryngeal malignancies. It shows that it is possible to cure laryngeal tumors (both squamous cell carcinomas and sarcomas) using PDT primarily, and that the cure rate as well as outcome of voice and patient safety is comparable to the conventional treatment modalities.

PDT can also be used as a function and organ sparing treatment for recurring laryngeal cancers, both squamous cell carcinomas and sarcomas.

Place, publisher, year, edition, pages
Örebro: Örebro university, 2014. p. 74
Series
Örebro Studies in Medicine, ISSN 1652-4063 ; 110
Keywords
Photo Dynamic Therapy, Cancer, Skin, Larynx, 5-ALA, UVradiation, sarcoma, squamous cell carcinoma, porfimer sodium, temoporfin, voice
National Category
Surgery
Research subject
Surgery
Identifiers
urn:nbn:se:oru:diva-35953 (URN)978-91-7529-039-3 (ISBN)
Public defence
2014-09-19, Universitetssjukhuset, B-hus aulan, Södra Grev Rosengatan, Örebro, 09:00 (Swedish)
Opponent
Supervisors
Available from: 2014-08-14 Created: 2014-08-14 Last updated: 2017-10-17Bibliographically approved
von Beckerath, M., Juzenas, P., Löfgren, L., Ma, L.-W., Iani, V., Malik, Z. & Moan, J. (2006). Influence of physiological parameters on the production of protoporphyrin IX in human skin by topical application of 5-aminolevulinic acid and its hexylester. Journal of Medical Sciences, 6(4), 546-553
Open this publication in new window or tab >>Influence of physiological parameters on the production of protoporphyrin IX in human skin by topical application of 5-aminolevulinic acid and its hexylester
Show others...
2006 (English)In: Journal of Medical Sciences, ISSN 1682-4474, E-ISSN 1812-5727, Vol. 6, no 4, p. 546-553Article in journal (Refereed) Published
Abstract [en]

Formation of protoporphyrin IX (PpIX) after topical application of 5-aminolevulinic acid (ALA) and its hexylester derivative (ALA-Hex) was studied on healthy human skin. Temperature, density of hair follicles, epidermal and skin thickness were measured on the application sites. The skin temperature was found to be the strongest determinant for PpIX formation. The PpIX fluorescence increase was about 25% per degree Celsius. Formation of PpIX was found to be independent of the density of hair follicles. A weak correlation was found between the PpIX fluorescence and the thickness of epidermis and skin. Sun exposure seems to reduce the production of PpIX slightly.

Place, publisher, year, edition, pages
A N S I Network, 2006
Keywords
5-aminolevulinic acid esters, Epidermal thickness, Fluorescence, Hair follicles, Skin physiology, Skin thickness, Spectroscopy, Temperature, aminolevulinic acid, aminolevulinic acid hexyl ester, protoporphyrin, adult, article, controlled study, correlation analysis, density, epidermis, fluorescence analysis, hair follicle, human, human experiment, male, normal human, ointment, protein synthesis, skin temperature, skinfold thickness, sun exposure, volunteer
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Research subject
Microbiology; Molecular Cellbiology
Identifiers
urn:nbn:se:oru:diva-38183 (URN)10.3923/jms.2006.546.553 (DOI)- ()- (PubMedID)2-s2.0-33750387149 (Scopus ID)
Available from: 2014-10-27 Created: 2014-10-27 Last updated: 2018-02-20Bibliographically approved
von Beckerath, M., Juzenas, P., Ma, L.-W., Iani, V., Lofgren, L. & Moan, J. (2001). The influence of UV exposure on 5-aminolevulinic acid-induced protoporphyrin IX production in skin. Photochemistry and Photobiology, 74(6), 825-828
Open this publication in new window or tab >>The influence of UV exposure on 5-aminolevulinic acid-induced protoporphyrin IX production in skin
Show others...
2001 (English)In: Photochemistry and Photobiology, ISSN 0031-8655, E-ISSN 1751-1097, Vol. 74, no 6, p. 825-828Article in journal (Refereed) Published
Abstract [en]

The skin of nude mice was exposed to erythemogenic doses of UV radiation, which resulted in erythema with edema. An ointment containing 5-aminolevulinic acid (ALA) was topically applied on mouse and human skin. Differences in the kinetics of protoporphyrin accumulation were investigated in normal and UV-exposed skin. At 24 and 48 h after UV exposure, skin produced significantly less protoporphyrin IX (PpIX) than skin unexposed to UV. Human skin on body sites frequently exposed to solar radiation (the lower arm) also produced less PpIX than skin exposed more rarely to the sun (the upper arm). It is concluded that UV radiation introduces persisting changes in the skin, relevant to its capability of producing PpIX from ALA. The observed differences in ALA-induced PpIX fluorescence may be the result of altered penetration of ALA through the stratum corneum or altered metabolizing ability of normal and UV-exposed skin (or both).

National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Research subject
Molecular Cellbiology; Microbiology
Identifiers
urn:nbn:se:oru:diva-38179 (URN)10.1562/0031-8655(2001)0740825TIOUEO2.0.CO2 (DOI)000172863800012 ()11783939 (PubMedID)2-s2.0-0035790603 (Scopus ID)
Note

The present work was supported by the Research Foundation of the Norwegian Radium Hospital and by the Örebro Medical Center Hospital. The authors are thankful to Even Angell-Petersen and Saulius Bagdonas for their help during the experiment.

Available from: 2014-10-27 Created: 2014-10-27 Last updated: 2017-12-05Bibliographically approved
Johansson, B., Karlsson, L., Reizenstein, J., von Beckerath, M., Hardell, L. & Persliden, J.Long term results from a uniform clinical series on pulsed dose rate brachytherapy as the boost to external beam irradiation in base of tongue cancer.
Open this publication in new window or tab >>Long term results from a uniform clinical series on pulsed dose rate brachytherapy as the boost to external beam irradiation in base of tongue cancer
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Background and purpose: To evaluate the long time outcome with regard to local tumour control, side effects and quality of life of a combined pulsed dose rate (PDR) boost and hyperfractionated accelerated external beam radiotherapy (EBRT) for primary base of tongue (BOT) cancers.

Patients and methods: Between 1994 and 2007 we treated 83 patients, median age 60 (38-82) years, with primary T1-T4 BOT cancers. Seven patients (8 %) were T1-2N0 (AJCC stage I-II) and 76 (92 %) patients were T1-2N+ or T3-4N0-3 (AJCC stage III-IV). The mean estimated primary tumour volume was 15 (1-75) cm3.  EBRT was given with 1.7 Gy twice daily to 40,8 Gy to primary tumour and bilateral neck lymph nodes in 2.5 weeks. A PDR boost of 35 Gy and a neck dissection in clinical node positive cases was performed 2-3 weeks later. The patients were followed for a median of 54 (2-168) months.

Results: The 2-, 5- and 10-years rates of actuarial local control were 91 %, 89 % and 85 %, overall survival 85 %, 65 % and 44 %, disease free survival 86 %, 80 % and 76 % respectively. The regional contral rate was 95 %. Six patients (7 %) developed distant metastases. Analysis of dosimetry showed a mean treated volume of 58 cm3.  In a review of late complications we found 11 (13 %) minor and 4 (5 %) major soft tissue necroses and 6 (7 %) osteoradionecroses. The patients median subjective SOMA/LENT scoring at last follow up was; grade 0 for pain and trismus, grade 1 for dysphagia and taste alteration and grade 2 for xerostomia. Global visual-analog-scale (VAS) scoring of quality of life was 8.

Conclusions: Local and regional tumour control rate was excellent in this treatment protocol. The data support that PDR boost is at least as effective as published continuous low dose rate (CLDR) results.

Keywords
Brachytherapy; Pulsed dose rate; Base of Tongue cancer; Outcome; Radio-therapy
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-10406 (URN)
Available from: 2010-04-20 Created: 2010-04-20 Last updated: 2017-10-18Bibliographically approved
Organisations

Search in DiVA

Show all publications